<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00790205</url>
  </required_header>
  <id_info>
    <org_study_id>0431-082</org_study_id>
    <secondary_id>2008_523</secondary_id>
    <secondary_id>2008-006719-20</secondary_id>
    <nct_id>NCT00790205</nct_id>
  </id_info>
  <brief_title>Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)</brief_title>
  <acronym>TECOS</acronym>
  <official_title>TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute, Oxford Diabetes Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment
      with sitagliptin used as part of usual care compared to usual care without sitagliptin in
      participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV)
      disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%.

      Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to
      usual care without sitagliptin with regard to the risk of developing a confirmed event in the
      primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus. If
      hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care,
      is superior to usual care without sitagliptin with regard to the risk of developing a
      confirmed event in the primary CV composite endpoint.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2008</start_date>
  <completion_date type="Actual">March 30, 2015</completion_date>
  <primary_completion_date type="Actual">March 30, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Incidence of All-cause Mortality (Per Protocol Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Incidence of All-cause Mortality (Intent to Treat Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Renal Function Over Time (Per Protocol Population)</measure>
    <time_frame>Baseline and up to 5 years</time_frame>
    <description>Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Renal Function Over Time (Intent to Treat Population)</measure>
    <time_frame>Baseline and up to 5 years</time_frame>
    <description>Change in renal function based on eGFR using the MDRD method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c Over Time (Per Protocol Population)</measure>
    <time_frame>Baseline and up to 4 years</time_frame>
    <description>HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c Over Time (Intent to Treat Population)</measure>
    <time_frame>Baseline and up to 4 years</time_frame>
    <description>HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)</measure>
    <time_frame>Baseline and up to 5 years</time_frame>
    <description>Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)</measure>
    <time_frame>Baseline and up to 5 years</time_frame>
    <description>Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14671</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>MK-0431</other_name>
    <other_name>JanuviaÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has T2DM

          -  Has HbA1c between 6.5% (48 mmol/mol) and 8.0% (64 mmol/mol) on stable dose(s) of
             antihyperglycemic agent(s), including insulin

          -  Has pre-existing cardiovascular disease

        Exclusion Criteria:

          -  Has a history of type 1 diabetes mellitus or ketoacidosis.

          -  Is not able to take sitagliptin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013 Dec;166(6):983-989.e7. doi: 10.1016/j.ahj.2013.09.003. Epub 2013 Oct 23.</citation>
    <PMID>24268212</PMID>
  </results_reference>
  <results_reference>
    <citation>Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, Holman RR; TECOS Executive Committee. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015 Apr;17(4):395-402. doi: 10.1111/dom.12441. Epub 2015 Feb 13.</citation>
    <PMID>25600421</PMID>
  </results_reference>
  <results_reference>
    <citation>Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.</citation>
    <PMID>26052984</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2008</study_first_submitted>
  <study_first_submitted_qc>November 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2008</study_first_posted>
  <results_first_submitted>March 15, 2016</results_first_submitted>
  <results_first_submitted_qc>March 15, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 14,671 participants were randomized to treatment, provided consent and did not have any Good Clinical Practice (GCP) deviations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7332"/>
                <participants group_id="P2" count="7339"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="7266"/>
                <participants group_id="P2" count="7274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6972"/>
                <participants group_id="P2" count="6905"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="360"/>
                <participants group_id="P2" count="434"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
                <participants group_id="P2" count="363"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7332"/>
            <count group_id="B2" value="7339"/>
            <count group_id="B3" value="14671"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age is unknown for 320 participants</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adults 18 - 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3315" spread="7.9"/>
                    <measurement group_id="B2" value="3301" spread="8.0"/>
                    <measurement group_id="B3" value="6616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From 65 - 84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3813"/>
                    <measurement group_id="B2" value="3821"/>
                    <measurement group_id="B3" value="7634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years and over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2134"/>
                    <measurement group_id="B2" value="2163"/>
                    <measurement group_id="B3" value="4297"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5198"/>
                    <measurement group_id="B2" value="5176"/>
                    <measurement group_id="B3" value="10374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <description>Sitagliptin, n= 7254; Placebo, n= 7274; Total, n=14528</description>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.9" spread="21.3"/>
                    <measurement group_id="B2" value="74.9" spread="20.9"/>
                    <measurement group_id="B3" value="74.9" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c (HbA1c)</title>
          <description>Sitagliptin, n= 7330; Placebo, n= 7336; Total, n= 14666</description>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="0.5"/>
                    <measurement group_id="B2" value="7.2" spread="0.5"/>
                    <measurement group_id="B3" value="7.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine albumin creatinine ratio</title>
          <description>Sitagliptin, n= 2606; Placebo, n= 2542; Total, n= 5148</description>
          <units>g/mol Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="37.4"/>
                    <measurement group_id="B2" value="8.4" spread="36.0"/>
                    <measurement group_id="B3" value="8.5" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)</title>
        <description>Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Confirmed Cardiovascular (CV) Event of Major Adverse Cardiovascular Event (MACE) Plus (Per Protocol Population)</title>
          <description>Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7257"/>
                <count group_id="O2" value="7266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6"/>
                    <measurement group_id="O2" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hazard Ratio of Sitagliptin/Placebo: the between-treatment difference in time to the first primary composite CV outcome measure was assessed by the hazard ratio between the sitagliptin and placebo groups. The confidence interval for the hazard ratio was computed and compared to 1.30, the non-inferiority margin.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.88</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)</title>
        <description>Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Confirmed CV Event of Major Adverse Cardiovascular Event (MACE) Plus (Intent to Treat Population)</title>
          <description>Primary composite CV endpoint of MACE plus which includes CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7332"/>
                <count group_id="O2" value="7339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hazard Ratio of Sitagliptin/Placebo: the between-treatment difference in time to the first primary composite CV outcome measure was assessed by the hazard ratio between the sitagliptin and placebo groups. The confidence interval for the hazard ratio was computed and compared to 1.30, the non-inferiority margin.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)</title>
        <description>CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Confirmed CV Event of MACE (Per Protocol Population)</title>
          <description>CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7257"/>
                <count group_id="O2" value="7266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4"/>
                    <measurement group_id="O2" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hazard Ratio of Sitagliptin/Placebo: the between-treatment difference in time to the first primary composite CV outcome measure was assessed by the hazard ratio between the sitagliptin and placebo groups. The confidence interval for the hazard ratio was computed and compared to 1.30, the non-inferiority margin.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)</title>
        <description>CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With First Confirmed CV Event of MACE (Intent to Treat Population)</title>
          <description>CV composite endpoint of MACE which includes CV-related death, nonfatal MI, or nonfatal stroke.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7332"/>
                <count group_id="O2" value="7339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Hazard Ratio of Sitagliptin/Placebo: the between-treatment difference in time to the first primary composite CV outcome measure was assessed by the hazard ratio between the sitagliptin and placebo groups. The confidence interval for the hazard ratio was computed and compared to 1.30, the non-inferiority margin.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Incidence of All-cause Mortality (Per Protocol Population)</title>
        <description>Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Incidence of All-cause Mortality (Per Protocol Population)</title>
          <description>Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7257"/>
                <count group_id="O2" value="7266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio of Sitagliptin/Placebo: The between-treatment difference in mortality due to all causes was assessed by the hazard ratio between the Sitagliptin and Placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.435</p_value>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Incidence of All-cause Mortality (Intent to Treat Population)</title>
        <description>Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Incidence of All-cause Mortality (Intent to Treat Population)</title>
          <description>Percent incidence of all-cause mortality is reported as the percentage of participants who died due to any cause.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7332"/>
                <count group_id="O2" value="7339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio of Sitagliptin/Placebo: The between-treatment difference in mortality due to all causes was assessed by the hazard ratio between the Sitagliptin and Placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.875</p_value>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)</title>
        <description>Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Incidence of Congestive Heart Failure (CHF) Requiring Hospitalization (Per Protocol Population)</title>
          <description>Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7257"/>
                <count group_id="O2" value="7266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="1.00" upper_limit="1.53"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.84" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio of Sitagliptin/Placebo: The between-treatment difference in CHF cases requiring hospitalization was assessed by the hazard ratio between the Sitagliptin and Placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.858</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group and history of CHF at baseline as explanatory variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)</title>
        <description>Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Incidence of CHF Requiring Hospitalization (Intent to Treat Population)</title>
          <description>Percent incidence of CHF requiring hospitalization was reported as the percentage of participants who were admitted to the hospital for CHF.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7332"/>
                <count group_id="O2" value="7339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="1.00" upper_limit="1.53"/>
                    <measurement group_id="O2" value="3.1" lower_limit="0.84" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hazard Ratio of Sitagliptin/Placebo: The between-treatment difference in CHF cases requiring hospitalization was assessed by the hazard ratio between the Sitagliptin and Placebo groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.983</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group and history of CHF at baseline as explanatory variables.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Renal Function Over Time (Per Protocol Population)</title>
        <description>Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method.</description>
        <time_frame>Baseline and up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data. Number of participants analyzed consists of those participants with a baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Renal Function Over Time (Per Protocol Population)</title>
          <description>Change in renal function based on estimated glomerular filtration rate [eGFR] using the Modification of Diet in Renal Disease [MDRD] method.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data. Number of participants analyzed consists of those participants with a baseline value.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7182"/>
                <count group_id="O2" value="7203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4; Sitagliptin, n= 3859; Placebo, n= 3864</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="14.2"/>
                    <measurement group_id="O2" value="-0.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8; Sitagliptin, n= 3562; Placebo, n= 3501</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="14.9"/>
                    <measurement group_id="O2" value="-0.9" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12; Sitagliptin, n=4912, Placebo, n=4778</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="15.8"/>
                    <measurement group_id="O2" value="-0.5" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24; Sitagliptin, n=4782, Placebo, n=4637</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="17.9"/>
                    <measurement group_id="O2" value="-1.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36; Sitagliptin, n=2776, Placebo, n=2614</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="18.0"/>
                    <measurement group_id="O2" value="-1.6" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48; Sitagliptin, n=1096, Placebo, n=1056</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="18.3"/>
                    <measurement group_id="O2" value="-2.8" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60; Sitagliptin, n=79, Placebo, n=88</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="18.2"/>
                    <measurement group_id="O2" value="-6.4" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Renal Function Over Time (Intent to Treat Population)</title>
        <description>Change in renal function based on eGFR using the MDRD method.</description>
        <time_frame>Baseline and up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation. Number of participants analyzed consists of those participants with a baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Renal Function Over Time (Intent to Treat Population)</title>
          <description>Change in renal function based on eGFR using the MDRD method.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation. Number of participants analyzed consists of those participants with a baseline value.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7254"/>
                <count group_id="O2" value="7274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4; Sitagliptin, n=3949; Placebo, n=3977</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="14.3"/>
                    <measurement group_id="O2" value="-0.8" spread="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8; Sitagliptin, n=3687; Placebo, n=3648</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="14.8"/>
                    <measurement group_id="O2" value="-0.9" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12; Sitagliptin, n=5082; Placebo, n=5015</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="15.8"/>
                    <measurement group_id="O2" value="-0.5" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24; Sitagliptin, n=5157; Placebo, n=5071</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="17.9"/>
                    <measurement group_id="O2" value="-1.7" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36; Sitagliptin, n=3037; Placebo, n=2942</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="18.1"/>
                    <measurement group_id="O2" value="-1.6" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48; Sitagliptin, n=1237; Placebo, n=1210</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="18.4"/>
                    <measurement group_id="O2" value="-2.8" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60; Sitagliptin, n=93; Placebo, n=106</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="17.4"/>
                    <measurement group_id="O2" value="-5.7" spread="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c Over Time (Per Protocol Population)</title>
        <description>HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.</description>
        <time_frame>Baseline and up to 4 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data. Number of participants analyzed consists of those participants with a baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c Over Time (Per Protocol Population)</title>
          <description>HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data. Number of participants analyzed consists of those participants with a baseline value.</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7250"/>
                <count group_id="O2" value="7258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4; Sitagliptin, n=6632, Placebo, n=6588</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.8"/>
                    <measurement group_id="O2" value="0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8; Sitagliptin, n=6294, Placebo, n=6197</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.9"/>
                    <measurement group_id="O2" value="0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12; Sitagliptin, n=6217, Placebo, n=6092</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24; Sitagliptin, n=5668, Placebo, n=5475</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.0"/>
                    <measurement group_id="O2" value="0.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36; Sitagliptin, n=3227, Placebo, n=3083</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.1"/>
                    <measurement group_id="O2" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48; Sitagliptin, n=1271, Placebo, n=1224</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.1"/>
                    <measurement group_id="O2" value="0.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60; Sitagliptin, n=106, Placebo, n=108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c Over Time (Intent to Treat Population)</title>
        <description>HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.</description>
        <time_frame>Baseline and up to 4 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation. Number of participants analyzed consists of those participants in the intent to treat population with a baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c Over Time (Intent to Treat Population)</title>
          <description>HbA1c is a measure of the percentage of glycated hemoglobin in the blood. Estimated mean difference between sitagliptin and placebo controlling for baseline HbA1c and region.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation. Number of participants analyzed consists of those participants in the intent to treat population with a baseline value.</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7325"/>
                <count group_id="O2" value="7331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4: Sitagliptin, n= 6772; Placebo, n= 6738</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.8"/>
                    <measurement group_id="O2" value="0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8: Sitagliptin, n= 6478; Placebo, n= 6414</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.9"/>
                    <measurement group_id="O2" value="0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12: Sitagliptin, n= 6448; Placebo, n= 6384</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24: Sitagliptin, n= 6105; Placebo, n= 5975</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.0"/>
                    <measurement group_id="O2" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36: Sitagliptin, n= 3521; Placebo, n= 3439</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.1"/>
                    <measurement group_id="O2" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48: Sitagliptin, n= 1432; Placebo, n= 1383</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.1"/>
                    <measurement group_id="O2" value="0.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60: Sitagliptin, n= 123; Placebo, n= 128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.0"/>
                    <measurement group_id="O2" value="0.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)</title>
        <description>Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.</description>
        <time_frame>Baseline and up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data. Number of participants analyzed consists of those participants with a baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Per Protocol Population)</title>
          <description>Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data. Number of participants analyzed consists of those participants with a baseline value.</population>
          <units>g/mol Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2590"/>
                <count group_id="O2" value="2522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4; Sitagliptin, n=664; Placebo, n=688</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="27.7"/>
                    <measurement group_id="O2" value="-1.4" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8; Sitagliptin, n=635; Placebo, n=597</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="38.5"/>
                    <measurement group_id="O2" value="0.2" spread="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12; Sitagliptin, n=1126; Placebo, n=1059</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="27.7"/>
                    <measurement group_id="O2" value="1.2" spread="33.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24; Sitagliptin, n=930; Placebo, n=892</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="34.0"/>
                    <measurement group_id="O2" value="3.2" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36; Sitagliptin, n=488; Placebo, n=513</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="24.0"/>
                    <measurement group_id="O2" value="4.0" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48; Sitagliptin, n=238; Placebo, n=233</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="15.2"/>
                    <measurement group_id="O2" value="1.5" spread="25.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60; Sitagliptin, n=13; Placebo, n=17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="10.1"/>
                    <measurement group_id="O2" value="4.8" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)</title>
        <description>Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.</description>
        <time_frame>Baseline and up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation. Number of participants analyzed consists of those participants in the intent to treat population with a baseline value for the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Albumin:Creatinine Ratio Over Time (Intent to Treat Population)</title>
          <description>Change from baseline reflects the difference between the urine albumin:creatinine ratio reported time point and baseline value.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation. Number of participants analyzed consists of those participants in the intent to treat population with a baseline value for the outcome measure.</population>
          <units>g/mol Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2606"/>
                <count group_id="O2" value="2542"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 4; n=677, n=713</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="27.5"/>
                    <measurement group_id="O2" value="-1.4" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 8; n=658, n=624</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="39.4"/>
                    <measurement group_id="O2" value="0.5" spread="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12; n=1167, n=1115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="30.2"/>
                    <measurement group_id="O2" value="1.2" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24; n=1011, n=964</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="33.1"/>
                    <measurement group_id="O2" value="3.1" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36; n=537, n=553</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="25.8"/>
                    <measurement group_id="O2" value="3.9" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48; n=265, n=256</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="16.3"/>
                    <measurement group_id="O2" value="1.6" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60; n=14, n=18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="9.7"/>
                    <measurement group_id="O2" value="6.4" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)</title>
        <description>Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Initiated Chronic Insulin Therapy (Per Protocol Population)</title>
          <description>Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5554"/>
                <count group_id="O2" value="5601"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6"/>
                    <measurement group_id="O2" value="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)</title>
        <description>Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Initiated Chronic Insulin Therapy (Intent to Treat Population)</title>
          <description>Chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5608"/>
                <count group_id="O2" value="5655"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7"/>
                    <measurement group_id="O2" value="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>0.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)</title>
        <description>In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Initiation of Co-interventional Agent (Per Protocol Population)</title>
          <description>In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral antihyperglycemic agent [AHA] or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)</description>
          <population>Per protocol population included all randomized participants who received study medication except those participants who did not contribute at least 1 day of data to the study analysis due to a major protocol violation that excluded all of their data.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7257"/>
                <count group_id="O2" value="7266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)</title>
        <description>In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)</description>
        <time_frame>Up to 5 years</time_frame>
        <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Initiation of Co-interventional Agent (Intent to Treat Population)</title>
          <description>In participants not receiving insulin at baseline, time to addition of first co-interventional agent (i.e., next oral AHA or chronic insulin, where chronic insulin therapy is defined as a continuous period of insulin use of more than 3 months.)</description>
          <population>Intent to treat population included all randomized participants who received study medication, provided consent, and did not have a major GCP deviation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7332"/>
                <count group_id="O2" value="7339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <method_desc>Model stratified by region with treatment group only as explanatory variable.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 68 months (including up to 28 days after last dose of study drug)</time_frame>
      <desc>All participants as treated (APaT) population includes participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo tablet taken orally once daily in the morning for up to approximately 5 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="928" subjects_at_risk="7266"/>
                <counts group_id="E2" subjects_affected="909" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="7266"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Autoimmune haemolytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hamartoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Syringomyelia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vitello-intestinal duct remnant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness bilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vertigo labyrinthine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colonic fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colonic pseudo-obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Duodenal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="7266"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="7266"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Jejunal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oedema mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal food impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Peptic ulcer perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pharyngo-oesophageal diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7266"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Small intestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Fat necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Mucosal hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="7266"/>
                <counts group_id="E2" events="31" subjects_affected="26" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Submandibular mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Biliary dyskinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal graft rejection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Acute hepatitis B</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Herpes simplex encephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Mycetoma mycotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="7266"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chemical burns of eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="7266"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7266"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Mouth injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Periorbital haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Periprosthetic osteolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prescribed overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Splinter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Testicular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tracheal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urinary bladder rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Anticoagulation drug level increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="7266"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle impingement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intervertebral disc compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="7266"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="54" subjects_affected="52" subjects_at_risk="7266"/>
                <counts group_id="E2" events="37" subjects_affected="35" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Abdominal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="7266"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of salivary gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenoid cystic carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Adenolymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anaplastic large-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Angioimmunoblastic T-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="50" subjects_affected="44" subjects_at_risk="7266"/>
                <counts group_id="E2" events="86" subjects_affected="55" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Basosquamous carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="7266"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bone sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Breast cancer in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the small bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="7266"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colon cancer stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colon cancer stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intraocular melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage I</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="7266"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="7266"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Meningeal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Meningioma malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metastatic uterine cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Mucinous adenocarcinoma of appendix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nasal cavity cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neoplasm recurrence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neurofibroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Oropharyngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian granulosa-theca cell tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="7266"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Penile cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Penile squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Plasmablastic lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pleomorphic liposarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pleural mesothelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Polycythaemia vera</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="7266"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage I</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage III</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Retroperitoneal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="38" subjects_affected="26" subjects_at_risk="7266"/>
                <counts group_id="E2" events="44" subjects_affected="38" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of head and neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="7266"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>T-cell prolymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thymic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tongue cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tonsil cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tracheal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tracheal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="7266"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urethral neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Complex partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Piriformis syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Posterior reversible encephalopathy syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Postictal state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Radiculitis lumbosacral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Retrograde amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Spinal cord disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Subdural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ulnar tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vertigo CNS origin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Drug dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nicotine dependence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Paranoid personality disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bladder stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="7266"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Stag horn calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="7266"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Calculus prostatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Orchitis noninfective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pelvic floor muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="18" subjects_affected="13" subjects_at_risk="7266"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Chronic respiratory disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="7266"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Laryngeal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Orthopnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="7266"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Tracheal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Dermatitis psoriasiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="7266"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Lymphorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7266"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7266"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study at least 30 days prior to submission for publication/presentation or at least 14 calendar days prior to submission for abstracts.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

